Monoclonal Anti-PSMA (mouse IgG1 isotype) is derived from the hybridoma 107-1A4 produced by the fusion of mouse myeloma cells and splenocytes from BALB/c mice. Prostate-specific membrane antigen (PSMA) is an integral, non-shed, type 2 transmembrane glycoprotein belonging to the M28 peptidase family.
Prostate-specific membrane antigen (PSMA), also known as glutamate carboxypeptidase II (GCPII), folate hydrolase 1 (FOLH1), is a 100kDa membrane glycoprotein, composed of 750 amino acids. PSMA gene with 19 exons and 18 introns is mapped to human chromosome 11p11–12. The encoded protein is detected in various type of tissues including kidney, prostate and brain. PSMA contains short cytoplasmic amino terminus, a single membrane-spanning domain and a large extracellular domain.
免疫原
prostate cancer LNCaP cells.
應用
Monoclonal Anti-PSMA antibody produced in mouse has been used in:
enzyme linked immuno sorbent assay (ELISA)
immunocytochemistry
immunoprecipitation
flow cytometry
生化／生理作用
Prostate-specific membrane antigen (PSMA), expressed in the brain, catalyzes the hydrolysis of N-acetyl-aspartyl glutamate to produce free glutamate. Elevated expression of the protein is associated with the development of prostate tumor. Mutations in PSMA leads to hyperhomocysteinemia. PSMA functions as a potential biomarker of prostate adenocarcinoma.
外觀
Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.
免責聲明
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Investigational antibody drug conjugates for solid tumors
Sapra P, et al.
Expert Opinion on Investigational Drugs, 20(8), 1131-1149 (2011)
Construction of Prostate-Specific Expressed Recombinant Plasmids With High Transcriptional Activity of Prostate-Specific Membrane Antigen (PSMA) Promoter/Enhancer
Zeng H
Journal of Andrology, 26, 215-221 (2005)
Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer.
Ghosh A and Heston WD
Journal of Cellular Biochemistry, 91, 528-539 (2004)
Prostate-specific membrane antigen (PSMA)-based imaging and therapy are increasingly used in the management of prostate cancer. However, low PSMA surface expression in certain patients is a limitation for PSMA-based technologies. We have previously shown that high doses of dutasteride, a
Glutamate carboxypeptidase II: a polymorphism associated with lower levels of serum folate and hyperhomocysteinemia
